Literature DB >> 1322163

Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil.

G M Pieper1, G J Gross.   

Abstract

The nitrovasodilator, nicorandil, is a clinically effective antianginal agent. We tested whether nicorandil may also possess anti-free-radical characteristics, since the nicotinamide moiety of its molecular structure is a known hydroxyl radical scavenger. In vitro production of hydroxyl radicals by hypoxanthine plus xanthine oxidase in the presence of iron produced a marked degradation of deoxyribose. Nicorandil and the structural analogs, nicotinic acid and nicotinamide, produced significant inhibition of deoxyribose breakdown at concentrations equipotent to the classical hydroxyl radical scavenger, mannitol. Nicorandil also produced a concentration-dependent inhibition of superoxide anion production by canine neutrophils that were activated with either phorbol myristate acetate (PMA) or opsonized zymosan. This inhibition could not be mimicked by the analog, nicotinamide. While equimolar concentrations of nitroglycerin produced less inhibition of superoxide anion generation in opsonized zymosan-activated neutrophils than that observed with nicorandil, nitroglycerin did not alter free-radical production in PMA-stimulated neutrophils. Glyburide, the ATP-sensitive potassium-channel blocker, did not reverse the action of nicorandil on neutrophils. Thus, nicorandil is a uniquely different nitrovasodilator with anti-free-radical and neutrophil-modulating properties.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322163     DOI: 10.1007/bf00051143

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  27 in total

Review 1.  Role of ion movements in neutrophil activation.

Authors:  R I Sha'afi; T F Molski
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

2.  Beneficial effects of iloprost in the stunned canine myocardium.

Authors:  N E Farber; G M Pieper; J P Thomas; G J Gross
Journal:  Circ Res       Date:  1988-02       Impact factor: 17.367

3.  Interaction between NO donors and iloprost in human vascular smooth muscle, platelets, and leukocytes.

Authors:  R J Gryglewski; R Korbut; E Trabka-Janik; A Zembowicz; M Trybulec
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

4.  Recovery of contractile function in post-ischaemic reperfused myocardium of conscious dogs: influence of nicorandil, a new antianginal agent.

Authors:  T M Shimshak; K C Preuss; G J Gross; H L Brooks; D C Warltier
Journal:  Cardiovasc Res       Date:  1986-08       Impact factor: 10.787

5.  Effect of cyclooxygenase blockade on the beneficial actions of nicorandil in the stunned myocardium of dogs.

Authors:  G J Gross; G M Pieper
Journal:  Pharmacology       Date:  1989       Impact factor: 2.547

6.  Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs.

Authors:  K M Mullane; N Read; J A Salmon; S Moncada
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

7.  Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion.

Authors:  S R Jolly; W J Kane; B G Hook; G D Abrams; S L Kunkel; B R Lucchesi
Journal:  Am Heart J       Date:  1986-10       Impact factor: 4.749

8.  Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate.

Authors:  G M Pieper; G J Gross
Journal:  Circulation       Date:  1987-10       Impact factor: 29.690

9.  Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil and nicorandil on canine large coronary arteries.

Authors:  K Satoh; H Yamada; N Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-01       Impact factor: 3.000

10.  Effects of SG-75 (nicorandil) on electrical activity of canine cardiac Purkinje fibers: possible increase in potassium conductance.

Authors:  S Imanishi; M Arita; T Kiyosue; M Aomine
Journal:  J Pharmacol Exp Ther       Date:  1983-04       Impact factor: 4.030

View more
  8 in total

1.  Synergistic effect of Nicorandil and Amlodipine on tissue defense system during experimental myocardial infarction in rats.

Authors:  Venkatachalem Sathish; Kesavarao Kumar Ebenezar; Thiruvengadam Devaki
Journal:  Mol Cell Biochem       Date:  2003-01       Impact factor: 3.396

2.  Nicorandil ameliorates posttransplant dysfunction in cardiac allografts harvested from non-heart-beating donors.

Authors:  Makoto Mohri; Kotaro Suehiro; Shu Yamamoto; Hiroki Yamaguchi; Kozo Ishino; Shunji Sano
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-10

3.  Protection by nicorandil against the dysfunction of the central vagal baroreflex system following transient global cerebral ischaemia in dogs.

Authors:  J Kurihara; N Ochiai; H Kato
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

4.  Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction.

Authors:  N Ikeda; T Yasu; N Kubo; S Hashimoto; Y Tsuruya; M Fujii; M Kawakami; M Saito
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

5.  Effect of nicorandil and amlodipine on bio-chemical parameters during isoproterenol induced myocardial necrosis in rats.

Authors:  Narinder Singh; Rahat Kumar
Journal:  Indian J Clin Biochem       Date:  2003-01

6.  Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes.

Authors:  Mari C Asensio-López; Fernando Soler; Domingo Pascual-Figal; Francisco Fernández-Belda; Antonio Lax
Journal:  PLoS One       Date:  2017-02-28       Impact factor: 3.240

Review 7.  Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Muli Wu; Zheng Huang; Haojun Xie; Zhongjiang Zhou
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

Review 8.  Hypothesis: The potential therapeutic role of nicorandil in COVID-19.

Authors:  Hend Ashour; Mohamed H Elsayed; Soha Elmorsy; Inas A Harb
Journal:  Clin Exp Pharmacol Physiol       Date:  2020-09-09       Impact factor: 2.963

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.